multiple myeloma2020update on diagnosis risk represents a topic that has garnered significant attention and interest. Multiplemyeloma: 2020update on diagnosis, risk-stratification and .... Each of the new biomarkers is associated with an approximately 80% risk of progression to symptomatic end-organ damage in two or more independent studies. The updated criteria represent a paradigm shift since they allow early diagnosis and initiation of therapy before end-organ damage.
Abstract Disease overview: Multiple myeloma accounts for approximately 10% of hematologic malignancies. Diagnosis: The diagnosis requires ≥10% clonal bone marrow plasma cells or a biopsy proven plasmacytoma plus evidence of one or more multiple myeloma defining events (MDE): CRAB In high‐risk patients, daratumumab, bortezomib, lenalidomide, dexamethasone (Dara‐VRd) is an alternative to VRd. Selected standard risk patients can get additional cycles of induction, and delay transplant until first relapse.
📝 Summary
The key takeaways from this article on multiple myeloma 2020 update on diagnosis risk highlight the value of being aware of this subject. By using these insights, one can make informed decisions.
For those who are just starting, or well-versed, there is always additional insights regarding multiple myeloma 2020 update on diagnosis risk.